Profile: Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

314.50DKK
3 Jul 2015
Change (% chg)

kr.-3.50 (-1.10%)
Prev Close
kr.318.00
Open
kr.316.50
Day's High
kr.318.00
Day's Low
kr.310.50
Volume
71,374
Avg. Vol
188,088
52-wk High
kr.393.00
52-wk Low
kr.106.50

Search Stocks
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Company Address

Bavarian Nordic A/S

Hejreskovvej 10A, Munkegarde
KVISTGAARD     3490

Company Web Links

Search Stocks